These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

185 related items for PubMed ID: 17470729

  • 1. Chronic myelogenous leukemia progenitors display a genetically unstable personality.
    Rodrigues MS, Sattler M.
    J Natl Cancer Inst; 2007 May 02; 99(9):662-3. PubMed ID: 17470729
    [No Abstract] [Full Text] [Related]

  • 2. Comparative In vitro cellular data alone are insufficient to predict clinical responses and guide the choice of BCR-ABL inhibitor for treating imatinib-resistant chronic myeloid leukemia.
    Laneuville P, Dilea C, Yin OQ, Woodman RC, Mestan J, Manley PW.
    J Clin Oncol; 2010 Apr 10; 28(11):e169-71; author reply e172. PubMed ID: 20194843
    [No Abstract] [Full Text] [Related]

  • 3. CML resistance to tyrosine kinase inhibitors: how is the laboratory to tell?
    Goldman J.
    Lab Hematol; 2004 Apr 10; 10(3):181-4. PubMed ID: 15529444
    [No Abstract] [Full Text] [Related]

  • 4. BCR-ABL in chronic myelogenous leukemia--how does it work?
    Goldman JM, Melo JV.
    Acta Haematol; 2008 Apr 10; 119(4):212-7. PubMed ID: 18566539
    [Abstract] [Full Text] [Related]

  • 5. New insights into the pathogenesis of chronic myeloid leukaemia: towards a path to cure.
    Thielen N, Ossenkoppele GJ, Schuurhuis GJ, Janssen JJ.
    Neth J Med; 2011 Oct 10; 69(10):430-40. PubMed ID: 22058262
    [No Abstract] [Full Text] [Related]

  • 6. Tyrosine kinase inhibitors for chronic myelogenous leukemia.
    Quintás-Cardama A, Kantarjian H, Cortes J.
    N Engl J Med; 2007 Oct 11; 357(15):1557; author reply 1557-8. PubMed ID: 17933034
    [No Abstract] [Full Text] [Related]

  • 7. Applying the discovery of the Philadelphia chromosome.
    Sherbenou DW, Druker BJ.
    J Clin Invest; 2007 Aug 11; 117(8):2067-74. PubMed ID: 17671641
    [Abstract] [Full Text] [Related]

  • 8. Imatinib resistance in CML.
    Volpe G, Panuzzo C, Ulisciani S, Cilloni D.
    Cancer Lett; 2009 Feb 08; 274(1):1-9. PubMed ID: 18653275
    [Abstract] [Full Text] [Related]

  • 9. Imatinib mesylate therapy in chronic myeloid leukaemia: the floodgates opened.
    Agarwal MB.
    J Assoc Physicians India; 2007 Feb 08; 55():99-100. PubMed ID: 17571737
    [No Abstract] [Full Text] [Related]

  • 10. Imatinib and chronic-phase leukemias.
    Boros LG, Lee WN, Cascante M.
    N Engl J Med; 2002 Jul 04; 347(1):67-8. PubMed ID: 12097546
    [No Abstract] [Full Text] [Related]

  • 11. Triptolide inhibits Bcr-Abl transcription and induces apoptosis in STI571-resistant chronic myelogenous leukemia cells harboring T315I mutation.
    Shi X, Jin Y, Cheng C, Zhang H, Zou W, Zheng Q, Lu Z, Chen Q, Lai Y, Pan J.
    Clin Cancer Res; 2009 Mar 01; 15(5):1686-97. PubMed ID: 19240172
    [Abstract] [Full Text] [Related]

  • 12. Interferon-alpha may restore sensitivity to tyrosine-kinase inhibitors in Philadelphia chromosome positive acute lymphoblastic leukaemia with F317L mutation.
    Potenza L, Volzone F, Riva G, Soverini S, Martinelli S, Iacobucci I, Gnani A, Barozzi P, Forghieri F, Morselli M, Zanetti E, Maccaferri M, Baccarani M, Martinelli G, Torelli G, Luppi M.
    Br J Haematol; 2009 Jul 01; 146(2):227-30. PubMed ID: 19545285
    [No Abstract] [Full Text] [Related]

  • 13. [STAT5, a new therapeutic target against the relapse of chronic myelogenous leukemia?].
    Casetti L, Martin-Lannerée S, Najjar I, Dusanter-Fourt I.
    Med Sci (Paris); 2013 Jul 01; 29(8-9):693-5. PubMed ID: 24005621
    [No Abstract] [Full Text] [Related]

  • 14. Monitoring treatment of chronic myeloid leukemia.
    Baccarani M, Pane F, Saglio G.
    Haematologica; 2008 Feb 01; 93(2):161-9. PubMed ID: 18245647
    [No Abstract] [Full Text] [Related]

  • 15. Dasatinib in chronic myelogenous leukemia.
    Chu SC, Tang JL, Li CC.
    N Engl J Med; 2006 Sep 07; 355(10):1062-3; author reply 1063-4. PubMed ID: 16960978
    [No Abstract] [Full Text] [Related]

  • 16. Instability of BCR-ABL gene in primary and cultured chronic myeloid leukemia stem cells.
    Jiang X, Saw KM, Eaves A, Eaves C.
    J Natl Cancer Inst; 2007 May 02; 99(9):680-93. PubMed ID: 17470736
    [Abstract] [Full Text] [Related]

  • 17. Imatinib resistance in a novel translocation der(17)t(1;17)(q25;p13) with loss of TP53 but without BCR/ABL kinase domain mutation in chronic myelogenous leukemia.
    Yamamoto K, Yakushijin K, Nishikawa S, Minagawa K, Katayama Y, Shimoyama M, Matsui T.
    Cancer Genet Cytogenet; 2008 May 02; 183(1):77-81. PubMed ID: 18474303
    [Abstract] [Full Text] [Related]

  • 18. Recent success with the tyrosine kinase inhibitor STI-571--lessons for targeted therapy of cancer.
    Shah NP, Sawyers CL.
    Curr Opin Investig Drugs; 2001 Mar 02; 2(3):422-3. PubMed ID: 11575716
    [No Abstract] [Full Text] [Related]

  • 19. Persistent neutropenia in chronic myelogenous leukemia in chronic phase treated with imatinib mesylate.
    Hwang YY, Tse E, So JC, Wan TS, Kwong YL.
    Am J Hematol; 2009 May 02; 84(5):302-5. PubMed ID: 19338042
    [No Abstract] [Full Text] [Related]

  • 20. Dynamics of BCR-ABL mutated clones prior to hematologic or cytogenetic resistance to imatinib.
    Ernst T, Erben P, Müller MC, Paschka P, Schenk T, Hoffmann J, Kreil S, La Rosée P, Hehlmann R, Hochhaus A.
    Haematologica; 2008 Feb 02; 93(2):186-92. PubMed ID: 18223278
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.